香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：1513） 2023年第一季度報告 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」或「公司」，連同其附 屬公司，統稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09條和第13.10B條以 及香港法例第571章證券及期貨條例第XIVA部內幕消息條文刊發本公告。 本公司及本公司董事會（「董事會」）全體成員保證信息披露的內容真實、準確、完整，沒有虛假 記載、誤導性陳述或重大遺漏。 重要內容提示： 1. 本公司董事會、監事會及董事、監事、高級管理人員保證公司2023年第一季度報告（「本 ...

[0 -> 28] 大家好欢迎参加力珠集团2022年业绩交流会目前所有参会者均处于静音状态现在开始Follow me的声明声明播报完毕后主持人可直接开始发言谢谢本次电话会议仅服务于新业证券客户会议音频及文字记录的内容版权为新业证券所有内容必须经新业证券审核后方可留存 [29 -> 51] 未经允许和授权转载转发此次会议内容均属侵权新义证券将保留追究其法律责任的权利电话会议所有参会人员不得泄露内幕信息以及未公开重要信息涉及外部嘉宾发言的新义证券不保障其发言内容的准确性与完整性 [51 -> 77] 深夜证券不承担外部嘉宾发言内容所引起的任何损失及责任不承担因转载转发引起的任何损失及责任市场有风险投资需谨慎提醒投资者注意投资风险审慎参考会议内容各位投资人上午好欢迎来到力柱集团2022年业绩交流会 [77 -> 105] 我們今天非常榮幸的邀請到公司管理層為我們線上解讀公司2022年的經營情況今天出席的公司領導有公司執行董事、總裁唐陽剛先生副董裁、財務負責人副董裁、董事會秘書楊亮先生研究院院長、化學藥首席科學家與務求公司總經理許堅先生我是興業證券的醫藥分析師黃漢陽 [105 -> 134] 那今天和我一同在线主持的 ...

Financial Performance - In 2022, the company achieved a revenue of RMB 12,629.58 million, representing a year-on-year growth of 4.69%[8] - The net profit attributable to shareholders was RMB 1,909.39 million, with a year-on-year increase of 7.53%[8] - The net cash flow from operating activities increased by 45.75% to CNY 2,772,671.30 thousand in 2022, compared to CNY 1,902,328.14 thousand in 2021[38] - The total assets as of December 31, 2022, were CNY 24,864,825.37 thousand, an increase of 11.14% from CNY 22,371,915.59 thousand in 2021[38] - The total liabilities increased by 23.17% to CNY 9,928,573.77 thousand in 2022, compared to CNY 8,060,890.80 thousand in 2021[38] - The basic earnings per share for 2022 was CNY 2.04, a 7.37% increase from CNY 1.90 in 2021[38] - The company's net assets attributable to shareholders increased by 6.71% to CNY 13,876,020.67 thousand in 2022, compared to CNY 13,003,763.63 thousand in 2021[38] - The company reported a decrease in the equity attributable to shareholders as a percentage of total assets to 55.81% in 2022, down from 58.13% in 2021[38] Dividends and Shareholder Returns - The company proposed a cash dividend of RMB 16.00 per 10 shares for the 2022 fiscal year, pending approval at the annual general meeting[8] - The board of directors has proposed a cash dividend of RMB 16.00 per 10 shares (including tax) for the 2022 fiscal year, pending approval at the annual general meeting[21] - The company will not issue bonus shares or conduct capital reserve transfers in the annual dividend plan[21] Research and Development - The company aims to enhance R&D efficiency and maintain its leading advantage in innovative drugs and complex formulations[13] - The company focuses on R&D innovation, particularly in unmet clinical needs, with a pipeline emphasizing innovative drugs and complex formulations[49] - The company has 26 ongoing key projects in R&D, with 5 in the production application stage and 3 in clinical trial approval stage[105] - The company has 86 ongoing research projects, with 1 in clinical stage and 15 technical improvement projects as of the end of 2022[108] - R&D expenses for the year totaled approximately RMB 1,401.27 million, a decrease of 8.01% from RMB 1,523.26 million in 2021, accounting for 11.10% of total revenue[103] Market and Product Development - The company is actively pursuing international collaboration opportunities to strengthen its market position and achieve sustainable development[11] - The company successfully launched the injection of Apalutamide in Indonesia, marking a significant milestone in international business expansion[57] - The company is focusing on innovative drug development in oncology, autoimmune diseases, and reproductive health, with several key projects progressing through clinical trials[62] - The company is advancing the development of a dual-valent vaccine against COVID-19 variants, with promising results in neutralizing efficacy against Omicron variants[60] - The company has completed the submission of registration materials for multiple products in overseas markets, with 19 product specifications approved in 11 countries/regions as of December 31, 2022[59] Corporate Social Responsibility - The company has committed approximately RMB 9.98 million to public welfare donations during the reporting period[12] - The company will continue to actively respond to national policy calls and strengthen social responsibility, focusing on providing precise assistance to chronic and rare disease populations[14] - The company aims to achieve carbon neutrality by 2055, emphasizing sustainable development and increasing investment in environmental protection[14] - The company expresses gratitude to shareholders, employees, and partners for their long-term support[14] Risk Management and Compliance - The company has analyzed potential risk factors and response strategies for future development in the management discussion and analysis section of the report[21] - The report includes forward-looking statements that may be affected by risks and uncertainties, and actual results may differ significantly[21] - The company emphasizes the importance of accurate and complete financial reporting, ensuring no misleading statements or omissions[20] Operational Efficiency - The marketing team enhanced professional and refined management, focusing on evidence-based and collaborative marketing strategies[11] - The company is enhancing its production and quality management systems to improve delivery capabilities and reduce operational costs, while promoting green production initiatives[58] - The company has established a comprehensive quality management system covering production, research, and sales processes, ensuring product safety and stability[78] Strategic Planning - The company anticipates that the Chinese pharmaceutical market will recover in 2023, with significant growth potential in the biopharmaceutical sector[13] - The company is focused on expanding overseas markets and advancing the consistency evaluation of related drugs to enhance competitiveness[195] - The company is prioritizing the development of high-value products and enhancing its market resilience through strategic planning and execution[183] Environmental Initiatives - The company is committed to energy conservation and emission reduction actions to meet its energy-saving and carbon reduction targets[14] - The company adheres to national environmental policies and regulations, increasing investment in environmental protection and aiming for carbon neutrality by 2055[199] Investment and Financing - The company reported a net increase in cash and cash equivalents of RMB 947.33 million, a significant improvement compared to a decrease of RMB 826.74 million in 2021[115] - The company received government subsidies amounting to RMB 183.35 million, contributing to 7.87% of total profit[120] - The total amount of funds raised by the company through a non-public offering was RMB 145,782.00 million, with RMB 142,030.04 million remaining after deducting issuance costs[165]

Financial Performance - The company achieved a revenue of RMB 12,629.58 million for the year 2022, representing a year-on-year growth of 4.69%[9] - The net profit attributable to shareholders for 2022 was RMB 1,909.39 million, an increase of 7.53% compared to the previous year[9] - Excluding non-recurring gains and losses, the net profit attributable to shareholders from core operations was RMB 1,880.46 million, reflecting a growth of 15.57% year-on-year[9] - The company reported a total revenue of RMB 12,629.58 million for the year, representing a year-on-year increase of 4.69%[17] - The net profit attributable to shareholders was RMB 1,909.39 million, reflecting a growth of 7.53% compared to the previous year[17] - The company achieved a net cash flow from operating activities of RMB 2,772.67 million, which is an increase of 15.57% year-on-year[17] - The basic earnings per share for 2022 was RMB 2.04, reflecting a 7.37% increase from RMB 1.90 in 2021[43] - The company's total assets as of December 31, 2022, were RMB 24,864,825.37 thousand, an 11.14% increase from RMB 22,371,915.59 thousand at the end of 2021[43] - The company's total liabilities increased by 23.17% to RMB 9,928,573.77 thousand in 2022, compared to RMB 8,060,890.80 thousand in 2021[43] - The return on equity attributable to shareholders was 13.76% in 2022, up from 13.66% in 2021[43] Research and Development - The company is focusing on innovative drug development in areas such as digestive, mental health, reproductive assistance, and oncology, with a differentiated product pipeline covering the entire R&D cycle[12] - The company has initiated Phase III clinical trials for several new products, including Semaglutide injection and Triptorelin microspheres[15] - Livzon's R&D investment reached 200 million CNY in 2022, accounting for 13% of total revenue, reflecting a strong commitment to innovation and new product development[36] - The company emphasizes research and development as the foundation for sustainable growth, targeting unmet clinical needs and focusing on innovative drugs and complex formulations[50] - The company has 26 ongoing key projects, with 5 in the production application stage and 3 in the clinical approval stage[103] - The number of R&D personnel increased to 973 in 2022, a growth of 3.95% compared to 936 in 2021[108] - The company has 86 ongoing research projects as of the end of 2022, with one project in the clinical evaluation stage[107] - The company is advancing research in dual-specific antibodies and NKT cell therapy, enhancing its R&D capabilities[68] Product Development and Innovation - The recombinant novel coronavirus fusion protein vaccine (Likan) was approved for emergency use in June 2022 and is now included in the national immunization program[12] - The company launched the recombinant humanized anti-IL-6R monoclonal antibody injection (Tocilizumab) in January 2023, enhancing the accessibility of medication for COVID-19 patients[12] - The company has made significant progress in the development of a recombinant COVID-19 vaccine, which was approved for emergency use and is now included in the national immunization program[65] - The company has enhanced its production capabilities by completing the construction of a new formulation workshop to meet market demand for vaccines[65] - The company’s monoclonal antibody injection for rheumatoid arthritis has been approved, contributing to alleviating supply shortages during the pandemic[67] - The company’s first pet formulation product, Pyriproxyfen and Moxidectin drops, was launched in 2022, marking a significant entry into the pet medicine market[69] Market Expansion and Strategy - The company plans to deepen market promotion and leverage digital and intelligent technologies to enhance sustainable development capabilities[15] - Livzon is actively pursuing strategic partnerships and potential acquisitions to bolster its product portfolio and expand its market reach[36] - The company plans to enhance its market presence in Southeast Asia, targeting a 20% increase in market share over the next three years[38] - The company is actively pursuing international market expansion, particularly in countries like Pakistan, Indonesia, and the Philippines[61] - The company is committed to international expansion and innovation-driven business models to enhance its global market presence[50] Corporate Governance and Social Responsibility - The total amount of public welfare donations made by the company during the reporting period was approximately RMB 9.98 million[16] - The company aims to achieve carbon neutrality by 2055 and is actively investing in environmental protection initiatives[16] - The company is committed to providing precise assistance to chronic and rare disease patients, contributing to health initiatives in rural areas[16] - The company received government subsidies amounting to RMB 183,348,565.80, contributing 7.87% to total profit[113] Financial Management and Investments - The company repurchased a total of 1,696,100 A-shares during the reporting period, utilizing a total of RMB 55,925,653.00[78] - The company has capital commitments of approximately RMB 406.79 million as of December 31, 2022, down from RMB 886.35 million at the end of 2021[143] - The investment amount for the year was RMB 40,000,152.05, representing a significant decrease of 95.49% compared to RMB 886,650,000.00 in the previous year[155] - The company is focusing on expanding its market presence through strategic investments in biotechnology and healthcare sectors[156] Risk Management - The report includes an analysis of potential risks and strategies for future development[20] - Forward-looking statements in the report are subject to risks and uncertainties, and actual results may differ significantly from these statements[20] - The company did not experience any changes in accounting policies or significant accounting errors during the reporting period[41]

Financial Performance - The company's operating revenue for Q3 2022 was CNY 3,185,688,204.81, representing a year-on-year increase of 1.66%[2] - Net profit attributable to shareholders for Q3 2022 was CNY 489,254,328.37, reflecting a significant increase of 25.37% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 462,530,618.00, up by 9.01% year-on-year[2] - The company's operating revenue for the first nine months of 2022 was RMB 9,488.25 million, a year-on-year increase of 1.27%[8] - The net profit attributable to shareholders for the first nine months of 2022 was RMB 1,506,800,118.40, compared to RMB 1,452,730,415.78 in the previous year, indicating an increase of about 3.73%[17] - The company's total operating profit for the first nine months of 2022 was RMB 1,872,605,981.76, slightly down from RMB 1,874,923,979.34 in the same period of 2021, indicating a decrease of about 0.12%[17] - The total comprehensive income for the period (January to September 2022) was approximately RMB 1.66 billion, an increase from RMB 1.45 billion in the same period of 2021, representing a growth of about 14.2%[18] Assets and Liabilities - The total assets at the end of the reporting period were CNY 23,569,873,466.33, an increase of 5.35% from the end of the previous year[3] - The total equity attributable to shareholders at the end of the reporting period was CNY 13,432,828,237.84, up by 3.30% from the previous year[3] - The total liabilities increased to RMB 9,058,494,489.03 at the end of the reporting period, compared to RMB 8,060,890,797.20 at the beginning of the year, marking an increase of about 12.35%[16] - The company's total non-current liabilities rose to RMB 2,324,476,858.20, compared to RMB 1,135,822,729.96 at the beginning of the year, reflecting an increase of approximately 104.8%[16] Cash Flow - The company's cash flow from operating activities for the period was CNY 1,847,923,769.75, showing a substantial increase of 41.57% year-on-year[2] - The net cash flow from operating activities rose by 41.57% to RMB 1,847.92 million, driven by increased sales receipts and reduced marketing expenses[9] - The net cash flow from investing activities was negative RMB 769 million, an improvement from negative RMB 1.37 billion in the same period of 2021[19] - The net cash flow from financing activities was negative RMB 757 million, which is an improvement compared to negative RMB 898 million in the previous year[20] Shareholder Information - The company had a total of 67,097 common shareholders at the end of the reporting period[10] - The company has a significant shareholder structure, with Hong Kong Central Clearing (Agent) Limited holding 309,562,240 shares, representing a major portion of the equity[12] - Health元药业集团股份有限公司 holds 221,376,789 shares, indicating its substantial stake in the company[12] Revenue Breakdown - The revenue from chemical products was RMB 5,571.60 million, a decrease of 3.40% year-on-year, with digestive products declining by 11.60%[8] - The revenue from raw materials and intermediates increased by 15.99% to RMB 2,499.26 million, indicating strong demand in this segment[8] Other Comprehensive Income - The company reported a significant increase in other comprehensive income after tax, rising by 163.56% to RMB 100.29 million, mainly due to foreign exchange fluctuations[8] - The company’s other comprehensive income attributable to shareholders of the parent company was RMB 97.61 million, a significant recovery from a loss of RMB 157.51 million in the same period of 2021[18] Research and Development - Research and development expenses for the first nine months of 2022 amounted to RMB 978,746,743.57, up from RMB 786,282,945.23 in the same period last year, reflecting a growth of approximately 24.5%[17] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[15]

Financial Performance - Livzon Pharmaceutical Group reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[15]. - The company's operating revenue for the current period is RMB 6,302,565,210.60, representing a 1.08% increase compared to the previous period's RMB 6,235,531,036.28[26]. - The total revenue for the reporting period reached RMB 6,239,730,885.56, representing a year-on-year increase of 0.74% compared to RMB 6,193,787,467.88 in the previous period[52]. - Livzon aims to achieve a revenue target of RMB 2.5 billion for the full year 2022, reflecting a growth rate of 12%[15]. - The net profit attributable to shareholders for the first half of 2022 was RMB 300 million, up 10% compared to the same period last year[15]. - Net profit attributable to shareholders for the current period is RMB 1,017,545,790.03, showing a decrease of 4.23% from RMB 1,062,475,917.41 in the previous period[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 13.73% to RMB 1,046,423,474.50 from RMB 920,069,483.32[26]. - The net profit of LIZHU PHARMACEUTICAL GROUP CO., LTD. for the first half of 2022 was approximately CNY 292.11 million, with a significant contribution from its subsidiary LIZHU GROUP FUZHOU FUXING PHARMACEUTICAL, which reported a net profit of CNY 266.88 million[110]. Research and Development - Livzon is investing RMB 200 million in R&D for new drug development, focusing on oncology and autoimmune diseases[15]. - The company focuses on R&D innovation, particularly in unmet clinical needs, with a strong emphasis on innovative drugs and complex formulations[31]. - The company is advancing high-barrier complex preparations, with several products in the clinical trial and approval stages, including long-acting microspheres[35]. - The company is committed to enhancing operational management and R&D efficiency to strengthen its competitive advantage in the market[34]. - The company aims to enhance its R&D capabilities by focusing on innovative drugs and complex formulations, aiming to strengthen its product pipeline and attract high-end R&D talent[114]. - The company is actively exploring market expansion opportunities in the health and pharmaceutical industries[90]. - The company has established a clear and rich product R&D pipeline, enhancing its competitive edge in the pharmaceutical industry[47]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia and Europe, targeting a 20% increase in international sales by the end of 2023[15]. - Livzon is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of RMB 500 million allocated for this purpose[15]. - The company is actively promoting its products in international markets, including Pakistan, Indonesia, the Philippines, Malaysia, and Uzbekistan, particularly in reproductive assistance and antifungal products[35]. - The company has established strategic partnerships with three international pharmaceutical firms to enhance its research capabilities and market access[15]. - The company is enhancing its international layout and actively pursuing innovative business cooperation models globally[31]. Financial Position and Assets - Total assets at the end of the period reached RMB 22,937,729,133.65, reflecting a 2.53% increase from RMB 22,371,915,590.82 at the beginning of the period[26]. - Total liabilities increased by 11.04% to RMB 8,950,902,250.48 from RMB 8,060,890,797.20[26]. - The company's total equity attributable to shareholders decreased by 1.05% to RMB 12,866,920,066.87 from RMB 13,003,763,631.47[26]. - Cash and cash equivalents at the end of the reporting period amounted to RMB 9,232,850,780.02, accounting for 40.25% of total assets, a decrease of 0.63% compared to the previous year[64]. - The asset-liability ratio increased from 36.03% as of December 31, 2021, to 39.02% as of June 30, 2022[70]. Operational Efficiency - The net cash flow from operating activities surged by 111.34% to RMB 1,426,385,813.18 compared to RMB 674,910,992.08 in the previous period[26]. - Total expenses, including sales, management, R&D, and financial expenses, amounted to RMB 2,717.46 million, a decrease of RMB 99.65 million or 3.54% year-on-year[57]. - The company has established a comprehensive marketing system with nearly 10,000 professional sales personnel covering major medical institutions and pharmacies nationwide[49]. - The quality management system has been continuously improved, ensuring the safety and stability of products, thereby enhancing market competitiveness[50]. Regulatory and Market Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[15]. - The company faced pricing pressure due to national drug procurement policies, with an average price reduction of 61.71% for 67 exclusive drugs negotiated in 2021[121]. - The company is actively monitoring national medical insurance policies and will enhance post-market clinical and pharmacoeconomic research in response to upcoming negotiations[122]. Corporate Governance and Compliance - The company has adhered to the Corporate Governance Code and the Standard Code as per the Hong Kong Listing Rules from January 1, 2022, to June 30, 2022[175][176]. - The board believes that the company's governance practices align with the requirements of the Corporate Governance Code and there are no discrepancies[174]. - The company has retained the auditing firm, Grant Thornton, for the 2022 fiscal year[185]. - The company has not experienced any significant litigation or arbitration matters during the reporting period[184]. Investment and Funding - The total amount of funds raised by the company through a private placement was RMB 145,782.00 million, with a net amount of RMB 142,030.04 million after deducting issuance costs[100]. - The company has committed to invest RMB 45,000,000 in the development and industrialization upgrade of the Aprazole series innovative products, with 76.69% of the investment completed by December 31, 2024[101]. - The company has not reported any significant investments, acquisitions, or disposals of subsidiaries during the reporting period[112]. - The company has adjusted its fundraising project for the development of monoclonal antibody drugs, reallocating a total of RMB 366 million for various projects, including RMB 143.29 million for a new pharmaceutical project[105]. Employee and Stock Options - The company continues to implement its stock option incentive plan and long-term partnership holding plan for employees[183]. - The total number of stock options held by middle management and key personnel (1,023 individuals) was 4,671,509, with 283,479 options exercised during the period[153]. - The company has approved amendments to the stock option incentive plan, stating that dividends will not adjust the exercise price of stock options[149]. Subsidiary Performance - The subsidiary, Lijun Group, reported a revenue of RMB 4,073.99 million and a net profit of RMB 716.47 million, contributing significantly to the overall financial performance[108]. - The subsidiary Sichuan Guangda reported a revenue of RMB 1,385.08 million and a net profit of RMB 21.14 million, reflecting its operational effectiveness[108].

Revenue and Profit - Revenue for Q1 2022 reached RMB 3,479,027,465.92, an increase of 3.86% compared to RMB 3,349,814,145.87 in the same period last year[2] - Net profit attributable to shareholders was RMB 553,293,797.77, reflecting a growth of 6.47% from RMB 519,651,078.57 year-on-year[2] - Net profit excluding non-recurring items increased by 15.61% to RMB 561,046,433.69 from RMB 485,302,200.16 in the previous year[2] - The company achieved operating revenue of RMB 3,479.03 million, a year-on-year increase of 3.86%[7] - Total profit for the current period was RMB 723,790,862.48, an increase from RMB 703,848,522.76 in the previous period, representing a growth of 2.68%[16] Earnings Per Share - The basic earnings per share for the quarter was RMB 0.59, up 5.36% from RMB 0.56 in the same period last year[2] - The diluted earnings per share increased by 7.27% to RMB 0.59 from RMB 0.55 year-on-year[2] - Basic earnings per share rose to 0.59, up from 0.56 in the previous period, reflecting a growth of 5.36%[17] Cash Flow - Operating cash flow net amount rose significantly by 38.03% to RMB 710,308,938.96 compared to RMB 514,620,182.77 in the same quarter last year[2] - The net cash flow from operating activities was RMB 710,308,938.96, representing a 38.03% increase compared to the previous year[8] - Cash inflow from financing activities totaled approximately ¥1.70 billion, an increase from ¥1.28 billion in the previous period, reflecting a growth of about 33%[19] - Net cash flow from financing activities was approximately ¥353.34 million, a turnaround from a negative cash flow of ¥82.49 million in the previous period[19] - The net increase in cash and cash equivalents was approximately ¥835.52 million, compared to ¥237.35 million in the previous period, representing an increase of about 252%[19] Assets and Liabilities - Total assets at the end of the reporting period were RMB 23,729,888,204.20, a 6.07% increase from RMB 22,371,915,590.82 at the end of the previous year[2] - Total current assets increased to RMB 15,807,296,634.71 from RMB 14,673,096,594.67, representing an increase of approximately 7.7%[14] - Total liabilities increased to RMB 8,799,314,102.16 from RMB 8,060,890,797.20, reflecting a growth of approximately 9.2%[15] - Short-term borrowings decreased by 31.19% to RMB 1,405,807,901.10, primarily due to repayments by subsidiaries[6] - Long-term borrowings increased significantly to RMB 1,626,661,809.48 from RMB 636,780,252.78, indicating a rise of approximately 155.5%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 57,995, including 57,970 A-share shareholders[9] - The top shareholder, Hong Kong Central Clearing Limited, holds 312,934,017 shares, representing 33.35% of the total shares[10] - Health元药业集团股份有限公司 is the second-largest shareholder with 221,376,789 shares, accounting for 23.59%[10] Other Financial Metrics - The company reported a significant increase in right-of-use assets by 52.95% due to new lease agreements signed during the period[6] - Research and development expenses increased to RMB 288,330,797.66, a rise of 24.5% from RMB 231,485,371.64 in the previous period[16] - The company’s financial expenses increased, with interest expenses rising to RMB 23,448,658.85 from RMB 14,068,040.27, indicating a rise of 66.5%[16] - The company reported a decrease in other comprehensive income, with a net amount of RMB -14,442,932.04 compared to RMB -123,910,341.14 in the previous period, showing improvement[17] - The company’s investment income from joint ventures and associates improved significantly to RMB 15,078,700.65, compared to a loss of RMB -3,506,817.44 in the previous period[16]